NATCO Pharma launches lenalidomide 2.5mg and 20mg in US

NATCO Pharma said that it has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in the strengths of 2.5mg and 20mg in the US.

The Indian pharma company has launched the product through its marketing partner Teva Pharmaceuticals, which is a US-based affiliate of Israeli pharma company Teva Pharmaceutical Industries.

With the launch, the Indian and Israeli pharma companies made available all the strengths of lenalidomide in the American market.

Lenalidomide capsules are a prescription drug for the treatment of multiple myeloma in adults.

Revlimid is owned by Celgene, a subsidiary of Bristol-Myers Squibb.